- Home
- HPAI vs CRBU Comparison
HPAI vs CRBU Comparison
Compare HPAI & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPAI
- CRBU
- Stock Information
- Founded
- HPAI 2023
- CRBU 2011
- Country
- HPAI Singapore
- CRBU United States
- Employees
- HPAI N/A
- CRBU N/A
- Industry
- HPAI
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- HPAI
- CRBU Health Care
- Exchange
- HPAI NYSE
- CRBU Nasdaq
- Market Cap
- HPAI 235.6M
- CRBU 236.3M
- IPO Year
- HPAI N/A
- CRBU 2021
- Fundamental
- Price
- HPAI $6.43
- CRBU $1.78
- Analyst Decision
- HPAI
- CRBU Strong Buy
- Analyst Count
- HPAI 0
- CRBU 4
- Target Price
- HPAI N/A
- CRBU $12.00
- AVG Volume (30 Days)
- HPAI 18.2K
- CRBU 1.5M
- Earning Date
- HPAI 12-31-2024
- CRBU 11-06-2024
- Dividend Yield
- HPAI N/A
- CRBU N/A
- EPS Growth
- HPAI N/A
- CRBU N/A
- EPS
- HPAI N/A
- CRBU N/A
- Revenue
- HPAI $29,575,625.00
- CRBU $11,475,000.00
- Revenue This Year
- HPAI N/A
- CRBU N/A
- Revenue Next Year
- HPAI N/A
- CRBU N/A
- P/E Ratio
- HPAI $32.37
- CRBU N/A
- Revenue Growth
- HPAI 132.36
- CRBU N/A
- 52 Week Low
- HPAI $3.07
- CRBU $1.50
- 52 Week High
- HPAI $14.74
- CRBU $8.33
- Technical
- Relative Strength Index (RSI)
- HPAI N/A
- CRBU 37.34
- Support Level
- HPAI N/A
- CRBU $1.82
- Resistance Level
- HPAI N/A
- CRBU $1.97
- Average True Range (ATR)
- HPAI 0.00
- CRBU 0.15
- MACD
- HPAI 0.00
- CRBU -0.03
- Stochastic Oscillator
- HPAI 0.00
- CRBU 6.25
About HPAI HELPORT AI LTD
Helport AI Ltd is a AI technology company based in Singapore dedicated to serving enterprises' customer contact centers with intelligent products, solutions, and a digital platform. Its software, Helport AI Assist (AI Assist), provides tailored AI-powered guidance and oversight for contact center interactions and customer experience, with functions including Agent Assistant, Quality Assurance (QA) Assistant, Supervisor Assistant, and Knowledge Base Assistant.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.